Lili Mao
Peking University(CN)Peking University Cancer Hospital(CN)Ministry of Education(ET)
Publications by Year
Research Areas
Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses
Most-Cited Works
- → Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification(2011)674 cited
- → Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma(2011)251 cited
- → Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma(2013)197 cited
- → The Placental Microbiome Varies in Association with Low Birth Weight in Full-Term Neonates(2015)194 cited
- → Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients(2019)186 cited
- → Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial(2019)165 cited